Challenges in developing drugs for the metabolic syndrome
- Glenn MatfinAffiliated withGlobal Medical and Scientific Affairs, Takeda America Holdings Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Metabolic syndrome refers to a clustering of established and emerging cardiovascular disease (CVD) risk factors within a single individual. The established risk factors—such as obesity, diabetes, dyslipidemia, hypertension—and other emerging risk factors are closely related to central obesity (especially intra-abdominal adiposity). Insulin resistance is also an important factor in this syndrome’s etiology. However, despite the potential use of having all the CVD risk factors under an umbrella diagnosis of metabolic syndrome, debate continues about the very existence of the metabolic syndrome. Despite the controversies, many existing therapies and new drugs in development are targeting the metabolic syndrome. To date, no drugs are approved specifically for treating the metabolic syndrome. This article discusses some of the challenges in developing therapies for the metabolic syndrome.
- Challenges in developing drugs for the metabolic syndrome
Current Diabetes Reports
Volume 8, Issue 1 , pp 31-36
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Glenn Matfin (1)
- Author Affiliations
- 1. Global Medical and Scientific Affairs, Takeda America Holdings, One Takeda Parkway, Deerfield, IL, 60015, USA